The FDA has approved rilzabrutinib (Wayrilz) as the first Bruton’s tyrosine kinase inhibitor for adults with chronic or persistent immune thrombocytopenia who have had an insufficient response to prior therapy.
Following court injunctions, some states and cities regained funding, while others experienced continued cancellations that affected immunization clinics, workforce capacity, and infectious-disease surveillance.
Emails and interviews show CDC scientists were sidelined during the West Texas surge, leaving local officials without guidance as cases spread across the US and into Mexico.
A rare carotid artery pseudoaneurysm complicated by MRSA infection, septic arthritis, and an incidental thigh tumor challenged clinicians but was successfully treated with surgery and targeted antibiotics.